![[höher]](/style/images/multi_up.png)
Eine Ebene höherGruppiert nach:
Dokumententyp
| Veröffentlichungsdatum
Springe zu: Zeitschriftenartikel
Anzahl der Publikationen: 4
Zeitschriftenartikel
Harbeck, Nadia; Gascon, Pere; Krendyukov, Andriy; Hoebel, Nadja; Gattu, Sreekanth und Blackwell, Kimberly
(2018):
Safety Profile of Biosimilar Filgrastim (Zarzio/Zarxio): A Combined Analysis of Phase III Studies.
In: Oncologist, Bd. 23, Nr. 4: S. 403-409
Harbeck, Nadia; Gascon, Pere; Jones, Clyde M.; Nixon, Allen; Krendyukov, Andriy; Nakov, Roumen; Li, Yuhan und Blackwell, Kimberly
(2017):
Proposed biosimilar pegfilgrastim (LA-EP2006) compared with reference pegfilgrastim in Asian patients with breast cancer: an exploratory comparison from two Phase III trials.
In: Future Oncology, Bd. 13, Nr. 16: S. 1385-1393
Blackwell, Kimberly; Donskih, Roman; Jones, C. Michael; Nixon, Allen; Vidal, Maria J.; Nakov, Roumen; Singh, Pritibha; Schaffar, Gregor; Gascon, Pere und Harbeck, Nadia
(2016):
A Comparison of Proposed Biosimilar LA-EP2006 and Reference Pegfilgrastim for the Prevention of Neutropenia in Patients With Early-Stage Breast Cancer Receiving Myelosuppressive Adjuvant or Neoadjuvant Chemotherapy: Pegfilgrastim Randomized Oncology (Supportive Care) Trial to Evaluate Comparative Treatment (PROTECT-2), a Phase III, Randomized, Double-Blind Trial.
In: Oncologist, Bd. 21, Nr. 7: S. 789-794
Harbeck, Nadia; Lipatov, Oleg; Frolova, Mona; Udovitsa, Dmitry; Topuzov, Eldar; Ganea-Motan, Doina Elena; Nakov, Roumen; Singh, Pritibha; Rudy, Anita und Blackwell, Kimberly
(2016):
Randomized, double-blind study comparing proposed biosimilar LA-EP2006 with reference pegfilgrastim in breast cancer.
In: Future Oncology, Bd. 12, Nr. 11: S. 1359-1367